Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Kim, D. W.; Goto, K.; Schram, A.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; Mercade, T. M.; Liu, S. V.; Al-Hallak, M. N.; Cleary, J.; Neuzillet, C.; Goto, Y.; Joe, A. K.; Adeyemi, S.; Jauhari, S.; Drilon, A. |
| Abstract Title: | Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) |
| Meeting Title: | ESMO Asia Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | S1702 |
| End Page: | S1703 |
| Language: | English |
| ACCESSION: | WOS:001122475400579 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2023.10.673 |
| Notes: | Meeting Abstract: 595P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work